Navigation Links
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Date:10/30/2010

atment regimens," said Greg Fanning PhD, head of hepatitis C research and development at Tibotec. "TMC435 is an important component of our growing HCV pipeline and we are encouraged by the results of the interim analysis presented at the AASLD meeting."

TMC435 is also being studied in HCV genotype-1 treatment-experienced patients who have failed treatment with peg-interferon and ribavirin. The ASPIRE study (Antiviral STAT-C Protease Inhibitor Regimen in Experienced patients; TMC435-C206; NCT00980330) is an ongoing global phase 2b randomized, double-blind, placebo controlled study in 463 patients.

In addition to the late-breaker oral presentation described above, data on TMC435 has been presented in 4 posters at AASLD:

278. "In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters." M.T. Huisman

812. "Virologic analysis of genotype-1-infected patients treated with once-daily TMC435 during the Optimal Protease inhibitor Enhancement of Response to Therapy (OPERA)-1 study." O. Lenz

895. "A Phase IIa, open-label study to assess the antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6." C. Moreno

1873. "Pharmacokinetic-pharmacodynamic analyses of TMC435 in patients infected with Hepatitis C Virus (HCV) genotypes 2 to 6." V. Sekar

About HCV

HCV is a blood-borne infectious disease that affects the liver.(1) With an estimated 170 million people infected worldwide(1) and three to four million people newly infected each year,(2) HCV puts a significant burden on patients and society. Chronic infection with HCV can lead to liver cancer and other serious and fatal liver diseases, and is the most common cause of liver transplant worldwide.(3)  Discovering and developing new treatments is very important to improving the standard of care for the millions of people living with this disease.

About Tibotec Pharmaceuticals

Tibotec
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2
... & Burling represented AstraZeneca in its $1.26 billion ... will pay $32 per share for all of ... (Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO  ) AstraZeneca ... primary focus on the discovery, development and commercialization ...
...  Melanie Pita, J.D., will offer her expert perspective ... hospitals as she presents "EHRs: Meaningful Use & ... Conference, being held  April 24-26, 2012, at the ... During the presentation, Pita, who serves ...
... Inc., a leading innovator of new life science tools, today ... of its innovative portable PCR system. The F1-12 system is ... high speed and sensitivity in a fully portable format. ... Standard Fast" speed levels delivering 30-cycle PCR amplification within ...
Cached Biology Technology:Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences 2Prognosis HIS Executive Slated To Offer EHR Advice At Illinois Rural Health Association Conference 2Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series 2
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure ... Industry Association today jointly announce the formation of ... release of its Identity and Biometric Entry ... The Framework received official support from BORDERPOL, the ... to improve and provide expertise regarding border security, ...
Breaking Biology News(10 mins):Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... $6 million grant from the National Heart, Lung and Blood ... Behavioral Intervention Trials to focus on reducing obesity and obesity-related ... "African-Americans and ... its related risks for diabetes and heart disease," says Dr. ...
... about in the body, they follow a complex pattern ... searching for food, a team of Vanderbilt researchers have ... development: Incorporating this basic behavior into computer simulations of ... development, bone remodeling, wound healing, infection and tumor growth, ...
... 2010) Van Andel Research Institute (VARI) researchers ... that line and protect the prostate in relation to the ... normal cells and cancer cells depend on different factors to ... cells without affecting normal cells when developing treatments. Prostate ...
Cached Biology News:Center aims to cut obesity in black, Latino New Yorkers 2Center aims to cut obesity in black, Latino New Yorkers 3Human cells exhibit foraging behavior like amoebae and bacteria 2Human cells exhibit foraging behavior like amoebae and bacteria 3VAI researchers develop tool to help study prostate cancer 2